GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunotech Biopharm Ltd (HKSE:06978) » Definitions » Inventories, Inventories Adjustments

Immunotech Biopharm (HKSE:06978) Inventories, Inventories Adjustments : HK$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Immunotech Biopharm Inventories, Inventories Adjustments?

Immunotech Biopharm's Inventories, Inventories Adjustments for the quarter that ended in Dec. 2024 was HK$0.00 Mil.


Immunotech Biopharm Inventories, Inventories Adjustments Historical Data

The historical data trend for Immunotech Biopharm's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunotech Biopharm Inventories, Inventories Adjustments Chart

Immunotech Biopharm Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Inventories Adjustments
Get a 7-Day Free Trial - - - - -

Immunotech Biopharm Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Inventories, Inventories Adjustments Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Immunotech Biopharm Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.


Immunotech Biopharm Business Description

Industry
Traded in Other Exchanges
N/A
Address
No.1 Kangding Street, 8th Floor, Block 1, Guosheng Technology Park, Beijing Economic-technological Development Area, Beijing, CHN, 100176
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
Executives
Jung Hyun Chul
Evodevo Ltd
Yan Kaijing 2501 Other
Xi Zang Jia Ze Chuang Ye Tou Zi You Xian Gong Si 2101 Beneficial owner
Jiang Su Ji Chuan Kong Gu Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Cao Longxiang 2201 Interest of corporation controlled by you
Cao Fei 2201 Interest of corporation controlled by you
Tian Jin Fu Hua De Ke Ji Kai Fa You Xian Gong Si 2501 Other
Yan Xijun 2501 Other
Wu Naifeng 2501 Other
Tasly (hong Kong) Pharmaceutical Investment Limited 2501 Other
Li Yunhui 2501 Other
Hua Run San Jiu Yi Yao Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
China Resources Pharmaceutical Group Limited 2201 Interest of corporation controlled by you
China Resources Company Limited 2201 Interest of corporation controlled by you

Immunotech Biopharm Headlines

No Headlines